Prophylactic treatment with activated prothrombin complex concentrate (FEIBA®) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors

Haemophilia

Volumn 13, Issue 3, 2007, Pages 249-255

  Leissinger, Cindy A ^a   Becton, D L ^b   Ewing, N P ^c   Valentino, L A ^d  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

aPCC; Arthropathy; Haemophilia; Inhibitor; Joint damage; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; BLEEDING; BLEEDING DISORDER; CHILD; CLINICAL ARTICLE; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HEMARTHROSIS; HEMOPHILIA A; HUMAN; INFANT; JOINT INJURY; LONG TERM CARE; MEDICAL AUDIT; PEROPERATIVE COMPLICATION; PHYSIOTHERAPY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; THROMBOSIS; TREATMENT OUTCOME; WALKING DIFFICULTY;

ADOLESCENT; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; HEMARTHROSIS; HEMOPHILIA A; HEMORRHAGE; HUMANS; INFANT; TREATMENT OUTCOME;

EID: 34248562674     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01442.x     Document Type: Article

References (28)

1. Mulder K, Llinas A. The target joint. Haemophilia 2004; 10(Suppl. 4): 152-6.
2. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558-63.
3. Kasper CK. Diagnosis and Management of Inhibitors to Factors VIII and IX. Treatment of Hemophilia Monograph Series, No. 34. Montreal, Canada: World Federation of Hemophilia, 2004.
4. Rodriguez-Merchan EC, Rocino A. Literature review of surgery management in inhibitor patients. Haemophilia 2004; 10(Suppl. 2): 22-9.
5. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 5(Suppl. 3): 25-32.
6. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Thromb Haemost 1997; 77: 1113-9.
7. Heisel MA, Gomperts ED, McComb JG, Hilgartner M. Use of activated prothrombin complex concentrate over multiple surgical episodes in a hemophilic child with an inhibitor. J Pediatr 1983; 102: 951-4.
8. Tjonnfjord GE, Brinch L, Gedde-Dahl T, Brosstad FR. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174-8.
9. Tjonnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: The updated Norwegian experience. Haemophilia 2004; 10(Suppl. 2): 41-5.
10. Wilde JT. Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors. Pathophysiol Haemost Thromb 2002; 32(Suppl. 1): 9-12.
11. Schino M, Centra A, Piseddu G, Sbrighi PS. APCC (FEIBA) home treatment prophylaxis in inhibitor haemophilia patients. Haemophilia 2000; 6: 294 [abstract 37].
12. Valentino L. FEIBA prophylaxis in patients with haemophilia A and inhibitors. Haemophilia 2004; 10(Suppl. 3): 115 [abstract 22 PO 18].
13. Kreuz W, Escuriola-Ettinghausen C, Martinez IC, Mentzer D, Figura S, Klarmann D. Efficacy and safety of factor VIII inhibitor bypass activity (FEIBA) for long-term prophylaxis in patients with high-responding inhibitors. Blood 2000; 96: 265a [abstract 1140].
14. Valentino L, Salit M. Prophylactic use of FEIBA in children with hemophilia complicated by high-titre inhibitors. Blood 2002; 100(Suppl. 1): 102B [abstract 3886].
15. Kreuz W, Escuriola-Ettinghausen C, Mentzer D et al. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors. Blood 2000; 96: 266a [abstract 1141].
16. Hilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261-8.
17. Brackmann HH, Lenk H, Scharrer I, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999; 5: 203-6.
18. Hilgartner MW. Current treatment of hemophilic arthropathy. Curr Opin Pediatr 2002; 14: 46-9.
19. Cohen I, Heim M, Martinowitz U, Chechick A. Orthopaedic outcome of total knee replacement in haemophilia A. Haemophilia 2000; 6: 104-9.
20. Manco-Johnson MJ, Abshire TC, Brown D et al. Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency. Blood 2005; 106: 6a [abstract 3].
21. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
22. Funk M, Schmidt H, Escuriola-Ettingshausen C et al. Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis. Ann Hematol 1998; 77: 171-4.
23. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? -The German experience. Haemophilia 1998; 4: 413-7.
24. Royal S, Schramm W, Berntorp E et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
25. Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999; 5(Suppl. 3): 11-7.
26. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
27. Ehrlich HJ, Henzl MJ, Gomperts, DE. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
28. Luu H, Ewenstein, B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10(Suppl. 2): 10-6.